tradmap

MLYS Earnings Mineralys Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$6 -$3 $0 2022 2023 2024 2025
EPS
Net income (annual)
-$178M -$89M $0 2022 2023 2024 2025
Net income
Return on equity (annual)
-93% -18% 57% 0% 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$4 -$2 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$241M -$121M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-44% -22% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–18 of 18
Q2 20262026-06-30-3.352026-08-1110-Q
Q1 20262026-03-31-0.472026-05-0610-Q
FY 20252025-12-31-2.292026-03-1210-K
Q3 20252025-09-30-1.942025-11-1010-Q
Q2 20262025-06-30-1.442026-08-1110-Q
Q1 20262025-03-31-0.792026-05-0610-Q
FY 20252024-12-31-3.662026-03-1210-K
Q3 20252024-09-30-2.682025-11-1010-Q
Q2 20252024-06-30-1.542025-08-1210-Q
Q1 20252024-03-31-0.702025-05-1210-Q
FY 20242023-12-31-1.992025-02-1210-K
Q3 20242023-09-30-1.362024-11-1210-Q
Q2 20242023-06-30-0.772024-08-1310-Q
Q1 20242023-03-31-0.512024-05-0910-Q
FY 20232022-12-31-5.772024-03-2110-K
Q3 20232022-09-30-4.022023-11-0710-Q
Q2 20232022-06-30-2.732023-08-0710-Q
Q1 20232022-03-31-1.482023-05-1510-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.